Amylyx makes $350M public stock offering in wake of avexitide results
· seekingalpha.com
Amylyx launches a $350M stock offering after avexitide phase 3 results sent shares up 64%. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...